[Ultratard HM, a new human insulin. Advantages as compared to current preparations?].
Ultratard HM, a new human insulin, was studied in 10 patients with type II diabetes mellitus not previously treated with insulin. A control group consisted of 12 patients on Protaphane HM and 22 patients on Monotard MC. All patients tolerated the treatment well. After 6 months of therapy antiinsulin antibodies were detectable in only one patient on Ultratard HM. Therefore, in adult diabetics it is difficult to demonstrate a difference of antigenicity between human and porcine insulin. In another study blood glucose profiles were compared in 7 stable diabetics on Ultratard HM and Monotard HM. In our patients there was no significant difference in the activity profile of these 2 insulins.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007328:Insulin / Q000276:immunology / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000032:analysis; D049528:Insulin, Long-Acting / Q000627:therapeutic use; D008875:Middle Aged
D001786:Blood Glucose; D003692:Delayed-Action Preparations; D007328:Insulin; D007330:Insulin Antibodies; D049528:Insulin, Long-Acting
Ultratard HM, ein neues Humaninsulin. Vorteile gegenüber den bisherigen Präparaten?